NASDAQ:CAMP CAMP4 Therapeutics Q3 2025 Earnings Results & Report $4.20 -0.13 (-3.00%) Closing price 04:00 PM EasternExtended Trading$4.19 -0.01 (-0.24%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CAMP4 Therapeutics missed analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.55 versus the -$0.47 consensus estimate, while revenue was $795 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 6, 2025TimeAfter Market ClosesConference Call DateNovember 5, 2025Conference Call6:00 PM ET CAMP4 Therapeutics EPS ResultsActual EPS-$0.55Consensus EPS -$0.47Beat/MissMissed by -$0.08One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCAMP4 Therapeutics Revenue ResultsActual Revenue$795 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly report(10-Q) CAMP4 Therapeutics Q3 2025 Earnings FAQ Did CAMP4 Therapeutics beat earnings estimates for Q3 2025? CAMP4 Therapeutics (NASDAQ:CAMP) reported earnings of -$0.55 per share for Q3 2025, missing the consensus estimate of -$0.47. The report was announced on Thursday, November 6, 2025. What was CAMP4 Therapeutics' revenue for Q3 2025? CAMP4 Therapeutics reported revenue of $795 thousand for Q3 2025. CAMP4 Therapeutics Earnings HeadlinesCAMP4 Therapeutics (NASDAQ:CAMP) Share Price Breaks Above Fifty Day Moving Average on Disappointing EarningsNovember 8 at 2:01 AM | americanbankingnews.comCAMP4 Reports Third Quarter 2026 Financial Results and Corporate HighlightsNovember 5, 2026 | finance.yahoo.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 11 at 1:00 AM | Porter & Company (Ad)CAMP4 Shares Rise After EU Clinical Trial Application ApprovalsOctober 27, 2026 | marketwatch.comCAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European UnionOctober 27, 2026 | globenewswire.comRaymond James initiates coverage of Camp4 Therapeutics with strong buyOctober 23, 2026 | msn.comSee More CAMP4 Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CAMP4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CAMP4 Therapeutics and other key companies, straight to your email. Email Address About CAMP4 TherapeuticsCAMP4 Therapeutics (NASDAQ:CAMP) is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit. CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes. Its programs are intended to work at the level of gene transcription and RNA regulation rather than by replacing defective genes or directly supplying missing proteins. The company’s lead program, CMP-CPS, is an orally administered small-molecule therapy designed to increase production of carbamoyl phosphate synthetase 1, an enzyme involved in the urea cycle. CAMP4 is investigating the program as a potential treatment for urea cycle disorders, including ornithine transcarbamylase deficiency. CAMP4 Therapeutics is headquartered in Cambridge, Massachusetts, and serves the biopharmaceutical market through the development of internally discovered therapeutics.View CAMP4 Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
